The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
November 5th 2024
Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.
Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care
December 12th 2012Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.
Read More
FDA Approves Afinitor for Advanced Breast Cancer
July 23rd 2012The United States Food and Drug Administration recently approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.
Read More
Preemptive Action: Reducing the Risk of Breast Cancer
June 14th 2012This continuing education activity addresses the factors that increase and decrease a woman's risk for breast cancer, and includes information for pharmacists to help provide evidence-based counseling on preventative measures.
Read More
FDA Approves Genentech, Inc's Perjeta for HER2-Positive Metastatic Breast Cancer
June 11th 2012The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read More
Bisphosphonates' Growing Role in Breast Cancer
June 15th 2008Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.
Read More